Figure 1

Endocannabinoid levels are dysregulated in MS patients compared to HD. (A) Principal component analysis of the endocannabinoid profile in HD and MS patients at baseline. HD (red) locate in a differentiated region of space compared to MS patients at baseline (blue) (B) Hierarchical clustering of HD and MS patients at baseline imputed from the four endocannabinoids (2-AG, AEA, OEA and PEA). HD are indicated with a C and their corresponding sample number . (C–F) Individual levels (in pmol/g of protein) of each endocannabinoid in HD and MS patients at baseline. MS patients presented lower levels of 2-AG and PEA. The Mann–Whitney test was used to compare differences between groups. Data are expressed as median with range. *p < 0.05; ****p < 0.0001; ns, not significant.